Idarucizumab reverses effects of dabigatran in emergencies



Team performing surgery
Photo by Piotr Bodze
Final results from the RE-VERSE AD trial suggest idarucizumab can reverse the anticoagulant effect of dabigatran etexilate mesylate in emergency situations. Patients who required dabigatran reversal because they needed urgent surgery were able to have their procedure a median of 1.6 hours from idarucizumab administration. In... [Read Article]

EC grants factor IX therapy orphan designation



Antihemophilic factor
The European Commission has granted orphan medicinal product designation to CB 2679d/ISU304, a clinical stage drug candidate for hemophilia B. CB 2679d/ISU304 is a next-generation coagulation factor IX variant that may allow for subcutaneous prophylactic treatment of individuals with hemophilia B. The product is being developed by Catalyst Biosciences, Inc. and... [Read Article]

Betrixaban receives FDA approval for VTE prophylaxis in adults



Doctor and hospitalized patient
Photo courtesy of CDC
The oral, once-daily factor Xa inhibitor betrixaban (Bevyxxa®) was granted approval by the US Food and Drug Administration (FDA) under Priority Review. Betrixaban is the first and only anticoagulant for hospital and extended duration prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical... [Read Article]